You searched for "Cancer"
Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel
This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...
Reducing the burden of NMIBC: outpatient laser management in morbid patients
With non-muscle invasive bladder cancer (NMIBC) posing a significant burden on urological departments, alternative ways of safely and effectively managing these patients with a minimally invasive approach is desirable. As rates of recurrence are high but progression rates low, and...
Testicular masses – can the testis be spared?
The standard practice for testicular masses confirmed on ultrasound has been to offer an inguinal orchidectomy, on the presumption that the mass represents testicular cancer. The growing use of scrotal ultrasound for various indications has led to an increase in...
Risk factors for BC after minimally invasive RNU
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...Understanding Stauffer’s syndrome
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...45th Congress of the Société Internationale d’Urologie (SIU)
IN PERSON registration fees include: Scientific Sessions (in person and virtual) Complimentary access to the 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting (Friday, October 31) Access to the Exhibit Hall Complimentary access to scientific content on the virtual congress platform, SIU@U, including live chats, virtual exhibit, gamification and session polling Access to the Congress Mobile App VIRTUAL registration fees include: Key Scientific Sessions broadcast live and available on-demand, including the Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting Full access to the virtual congress platform, SIU@U, including live chat, virtual exhibit, gamification and session polling Access to the Congress Mobile AppMUC (Midlands Urology Club) Annual Meeting
The Midlands Urology Club (MUC) Meeting is back in Walsall this year. An eminent panel of Urologists will be talking to us on various aspects of clinical practice. Talks include updates from Mr A Birring & Mr KJ Ho on Genito-Urethral Reconstruction Services and Management of Penile Cancer in West Midlands, respectively. Mr C Luscombe will be leading a session on Implementation of the GIRFT A&G in the region. The event is fully subscribed now with LEDS, NTN’s, FYs & CTS as well as senior clinicians registered for the meeting. This is an opportunity to learn, get up-to-date on local practice and meet fellow colleagues in the area. Audits from various trusts in the region will be presented in the afternoon. Lunch and refreshments have kindly been provided by our sponsors.
Long-term oncologic outcomes of salvage cryoablation for rrPC
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...BAUS Annual Scientific Meeting 2023
Day 1 Highlights by: Omer Abdalla, Urology ST6 - Wirral University Teaching Hospitals, Mersey BSoT Trainee's rep (@Omer_Uro1). BAUS 2023 began last night with a wonderful welcome reception at the Birmingham Library, where urologists from throughout the UK met again,...Clinical trials 1
Clinical Trials 2 is available here. Case 1 1. What are the levels of clinical evidence based on the 2009 definitions from the ‘Oxford CEBM’? 2. What is the null hypothesis? 3. What are type 1 and type 2 errors?...
